Literature DB >> 2606630

Response of tumors to therapy studied by 31P magnetic resonance spectroscopy.

G S Karczmar1, D J Meyerhoff, A Speder, F Valone, M Wilkinson, N Shine, M D Boska, M W Weiner.   

Abstract

Magnetic resonance (MR) methods have been used to study the metabolic and vascular response of model tumors to tumor necrosis factor (TNF). Magnetic resonance measurements demonstrated acute reductions in tumor blood flow, measured from tumor uptake of D2O, and in tumor adenosine triphosphate (ATP), measured by 31P magnetic resonance spectroscopy (MRS) following administration of TNF. The decrease in ATP generally followed reduction in tumor blood flow, and therefore was probably due to ischemia caused by damage to tumor vasculature. Superficial human tumors have been studied by MRS to characterize their 31P spectra, and to measure metabolic changes during therapy. The ratio of the intensities of the phosphomonoester (PME) and ATP resonances (PME/ATP) was much higher in tumors than in the normal tissue displaced by the tumors. During therapy, decreases in PME/ATP were detected that paralleled, but did not anticipate, decreases in tumor size. In some cases, a transient increase in PME/ATP was detected during therapy, which did not correlate with changes in tumor size, and which may reflect stimulation of cell growth in some tumor zones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606630     DOI: 10.1097/00004424-198912000-00022

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  2 in total

1.  Intracarotid recombinant human tumor necrosis factor-alpha reduces cerebral blood flow and methionine uptake in rat brain tumors.

Authors:  T Sasajima; K Mineura; M Kowada; J Hatazawa; S Miura
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

2.  Positron emission tomographic assessment of cerebral hemocirculation and glucose metabolism in malignant glioma following treatment with intracarotid recombinant human tumor necrosis factor-alpha.

Authors:  T Sasajima; K Mineura; J Sasaki; M Kowada; N Tomura; J Hatazawa; T Ogawa; K Uemura
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.